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Abstract
Background: Australia has one of the highest rates of methamphetamine use in the world; however, treatment
access for methamphetamine is comparatively low. This descriptive study aimed to identify patterns of treatment
utilization and perceived barriers to accessing treatment among dependent methamphetamine users in the hope
that such information will enable services to more appropriately respond to this group.
Methods: One hundred and twenty-six methamphetamine users who had a current or past history of
methamphetamine dependence were interviewed about their experiences of, and perceived barriers to, treatment.
Results: Treatment utilization among methamphetamine users was reportedly low. One of the main reasons cited
for not accessing treatment was that methamphetamine users did not perceive their drug use to be a problem
(despite apparent levels of dependence). Self-detoxification with the use of other licit and illicit drugs was high
among this group. Participants identified a lack of confidence in the ability of treatment services to address
methamphetamine dependence and the ‘opiate-centric’ nature of treatment services as significant blocks to
treatment entry. Suggestions for improvement by participants included operating specialist services for
methamphetamine users, placing an emphasis on responsiveness and routinely involving case management
services for this group.
Discussion and Conclusions: To improve service delivery, treatment services should reorient their services to
better address the needs of methamphetamine users by making small changes such as specific opening times for
methamphetamine users or using a dedicated space for methamphetamine treatment. Alternative options such as
online treatments and specialist methamphetamine clinics should be considered for methamphetamine users.
Introduction
The use of methamphetamine is of significant concern
to the community. Australia has one of the highest rates
of methamphetamine use in the world with over 6% of
the population reporting having tried the drug and over
2% currently using [1]. Australia also has one of the
highest rates of methamphetamine injecting in the
world, bringing with it additional harms and higher risk
of dependence [2].
There are estimated to be over 73,000 dependent
methamphetamine users in Australia [3], making up
approximately 11% of regular users. Yet treatment
utilization among methamphetamine users is relatively
low [4]. For example in Australia, methamphetamine
accounts for only 11.2% of total treatment presentations,
behind alcohol (44.5%) and cannabis (21.6%). Further,
methamphetamine has around the same number of
treatment presentations as heroin (10.5%) despite having
more than twice the number of dependent users [3,4].
The reasons for low treatment seeking among
methamphetamine users is not clear, but authors have
suggested a number of potential reasons including the
poor orientation of services to this group, lack of infor-
mation about treatment options and little confidence in
the effectiveness of these programs [5].
Lee and colleagues [6] have found that methampheta-
mine users can wait an average of five years from first
experiencing problems with their methamphetamine use
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when methamphetamine users do seek treatment, there
is a substantial likelihood of treatment dropout or
relapse [7].
While there has been some recent research into bar-
riers to treatment for illicit drug users more broadly,
there has been very little research on barriers specific to
methamphetamine treatment, particularly in Australia.
Barriers to effective service delivery for illicit drugs users
more generally include social stigma, perceptions about
treatment effectiveness, accessibility and long waiting
periods [8-12]. Barriers specific to methamphetamine
use, which were reported over a decade ago in the UK,
include methamphetamine users not identifying them-
selves as ‘hard’ or dependent drug users and being
unwilling to mix with heroin users [13]. Indeed, over
ten years ago, 65% of methamphetamine users in the
UK indicated that they perceived treatment services to
be inappropriate for them and not meeting their parti-
cular needs [14].
Pennay and Lee [15] recently identified barriers to
methamphetamine withdrawal treatment from the ser-
vice provider perspective, noting that service providers
saw barriers to methamphetamine treatment as extensive
and wide-ranging. Some of these barriers included: parti-
cular personality characteristics of methamphetamine
users, complexities associated with mental health comor-
bidity, waiting periods resulting in loss to treatment, the
binge nature of methamphetamine use complicating
withdrawal, lacking appropriate pharmacotherapy
options and negative attitudes of staff towards this group.
However, this study was from a service perspective view
and focused only on withdrawal treatment.
Through interviews with 126 dependent methamphe-
tamine users, the current study aimed to identify pat-
terns of treatment utilization and perceived barriers to
accessing treatment. By developing a comprehensive
understanding about the problems associated with
accessing treatment from the perspective of metham-
phetamine users, treatment services might be able to
better orient their services to overcome such barriers
and in turn, improve engagement and retention.
Methods
Participants
One hundred and twenty-six adult illicit methampheta-
mine users who met DSM-IV [16] criteria for past or
present methamphetamine dependence were interviewed
about their treatment utilization, experiences of treat-
ment and perceived barriers to treatment. Males com-
prised 71% (n = 89) of the sample, the average age was
32 years (SD = 8.6; range: 19-59 years) and 84% (n =
106) were Australian born. Fifty-seven percent (n = 72)
had either no qualifications or secondary school only
and 66% (n = 83) were unemployed at the time of the
survey.
Eighty-six percent (n = 102 of 119) of participants
identified their time of most frequent methamphetamine
use as ‘in the past’, ranging from one month to 28 years
prior to the time of interview (mean = 59.8 months; SD =
65.0). Eighty percent (n = 101) of participants had
used methamphetamine in the six months prior to the
interview, while 68% (n = 86) had used in the month
prior. Forty-two percent (n = 53) reported using
methamphetamine on at least four days in that month.
Sixty percent of the sample (n = 76) reported the age of
first use of methamphetamine between 15 and 18 years,
with 43% snorting (n = 54) and 36% (n = 45) injecting as
their first route of administration. Eighty percent (n =
101) had injected methamphetamine and the mean
Severity of Dependence score was 8.2 (SD = 2.5; range 4-
14 years), indicating high levels of dependence [17].
Methamphetamine was the most commonly cited drug
of choice (n = 43; 34%), but high levels of polydrug use
were evident in the sample. The substance used most
often by participants in the six months prior to interview
were methamphetamine (n = 39; 31%), cannabis (n = 26;
21%), heroin (n = 18; 14%) and alcohol (n = 15; 12%).
Previous experience of specialist alcohol and other
drug (AOD) treatment not related to methamphetamine
use was high (n = 74; 59%) and 40% (n = 50) of partici-
pants reported current engagement with AOD treat-
ment. The most common current treatment was opioid
pharmacotherapy programs (n = 33; 26%), followed by
counseling (n = 18; 14%).
Measures
A structured questionnaire delivered via notebook com-
puter using specifically designed software [18] asked
about a range of demographic variables and used a com-
bination of scaled response, multiple choice and open-
e n d e dq u e s t i o n sa b o u tu s e r s ’ experiences and attitudes
towards treatment.
The Severity of Dependence Scale (SDS) [17] was used
as a preliminary screening tool to indicate participant
eligibility for past or present methamphetamine depen-
dence. The SDS is a brief instrument that can be admi-
nistered over the telephone. A cut-off of four as
suggested by Topp and Mattick [19] was used as an
indication of past or present dependence. During the
interview, the Structured Clinical Interview for DSM-
IV-TR (SCID-I) [20], a semi-structured interview for
making the major DSM-IV Axis I diagnoses, was admi-
nistered as a more rigorous measure of methampheta-
mine dependence during the time of the participants’
most frequent use of the drug. While completing the
survey tool, participants were asked to reflect on their
most frequent period of methamphetamine use.
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Participants in metropolitan Melbourne were recruited
over 12 months from community health and specialist
AOD programs, public health services such as needle
and syringe programs, and the general public via adver-
tising in street press and online forums. Participants
were first screened over the telephone for eligibility
using the SDS. Eligible participants then met with a
researcher at a convenient and private location to com-
plete the questionnaire. The majority of the question-
naire could be self administered, and responses were
recorded directly onto a laptop computer. Self adminis-
tration was dependent on the participants’ level of lit-
eracy, computer skill and/or confidence. When
necessary or requested, the researcher read out sections
and entered responses with participant’sp e r m i s s i o n .
The SCID-I dependence measures were researcher-
administered only. The structured computer-delivered
interviews took around one hour, but on occasion took
as long as two hours. Participants were reimbursed $30
for their time. Ethics approval was granted for the study
from the Human Research Ethics Committee of the
Department of Human Services (now Department of
Health), Victoria, Australia. All procedures followed
were in accord with the standards of this committee.
Quantitative data was analyzed using SPSS version
14.0 and primarily involved descriptive and bivariate
analysis. Qualitative responses were extracted from
SPSS, and coded according to common themes. For the
majority of data reported, no more than 1-2% was miss-
ing and has been treated as missing data in descriptive
analysis. Reduced response rates are evident for some
variables, due to questionnaire sections directed only at
sub-samples of participants and resulting from partici-
pants who felt unable to respond (’don’t know’ or ‘refuse
to answer’ responses). The frequency of the latter may
have been increased due to self-administration of the
questionnaire. When significant, these reduced response
samples are indicated in the text.
Results
Treatment seeking among methamphetamine users
Based on a five point scale, 49% (n = 62) of participants
reported being well to very well informed about the
available options for methamphetamine treatment.
A further 37% (n = 46) indicated being moderately
informed.
Despite being well informed and although 65% (n = 80)
of the sample had ever perceived a need for treatment to
help with withdrawal, only 34% (n = 43) had actually
sought treatment for their methamphetamine use. Coun-
seling was the most frequently accessed treatment by the
sample (n = 28; 22%), followed by inpatient withdrawal
(n = 19; 15%) and Narcotics Anonymous (n = 14; 11%).
Table 1 shows participants’ awareness of different AOD
treatment options, and past utilization of treatment types
specific to managing methamphetamine withdrawal.
Participants reported self-detoxifying from metham-
phetamine more often than seeking formal treatment. Of
122 respondents to a series of closed category questions,
94% (n = 115) reported that most withdrawal attempts
were without professional support and 79% (n = 96) typi-
cally managed withdrawal from methamphetamine by
using other illicit drugs, alcohol or prescription medica-
tions to deal with symptoms. The sample had previously
undergone withdrawal using other drugs an average of
10.4 times (SD = 19.4), and four times ‘cold turkey’.
Reasons for treatment seeking
The 43 participants who had sought formal treatment
were asked their reasons (using a multiple response list
of options). Over two-thirds (n = 28) identified their pri-
mary reasons for accessing treatment as being sick of
the lifestyle, pressure from friends and family, and seek-
ing abstinence (Table 2).
Responses to a series of open ended questions found
that among those who had sought methamphetamine
treatment, one third (n = 14) had criticisms of treat-
ment, including difficulty with access, dissatisfaction
with the medication regime and poor treatment from
staff. A further nine participants referred to issues such
as the negative impact of treatment on their work,
family relationships and finances.
Barriers to methamphetamine treatment seeking
Thirty five percent of the sample (n = 43) reported they
had never felt the need to access formal treatment. The
primary reasons (drawn from a list of multiple responses)
included that they did not consider their drug use to be
Table 1 Awareness of AOD specific treatment options and
treatment utilization for methamphetamine withdrawal
management
Treatment option Treatment awareness
n (%) (n = 126)
Treatment utilization
n (%) (n = 125)
Drug counseling 121 (96%) 28 (22%)
Narcotics
Anonymous
113 (90%) 14 (11%)
Residential/
inpatient
withdrawal
98 (78%) 19 (15%)
Outpatient
withdrawal
73 (58%) 5 (4%)
General practitioner
(GP)
a
n/a 9 (7%)
Therapeutic
community
b
n/a 8 (6%)
aGP (not AOD specific).
bAwareness of therapeutic communities was not asked.
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treatment necessary (n = 13) or they did not consider
their drug use to be a problem (n = 10).
Of those who had ever felt a need for methampheta-
mine withdrawal treatment (n = 80), 83% (n = 67)
reported ever having a time when they felt a need for
h e l pb u td i dn o ta t t e m p tt os e e ki t .T h i sg r o u pw a s
asked to identify treatment barriers from an extensive
multiple response list (including the option to specify
‘other’). The main reasons preventing them from acces-
sing treatment included: the desire to attempt withdra-
wal on their own (n = 39; 57%), not knowing how to go
about accessing treatment (n = 28; 41%) and wanting to
keep using methamphetamine (n = 26; 38%) (Table 3).
Suggested improvements for methamphetamine
treatment
A small group of participants with no previous metham-
phetamine treatment experience and who reported they
would not contemplate going to an AOD treatment ser-
vice (n = 20) were asked what would attract them into
methamphetamine treatment. Response to this multiple
choice question (including an open ended ‘other’ option)
found nearly half (n = 9) called for effective counseling;
seven participants wanted a pharmacotherapy to assist
in the management of withdrawal, and six reported that
a specialist center for methamphetamine users would be
the only thing that would attract them into treatment.
The need for specialist methamphetamine centers was
highlighted in participants’ open ended responses to
their attitudes to, and perception of, currently available
formal treatment options. Of 121 respondents, 22 peo-
ple referred directly to a lack of stimulant focused or
appropriate treatment and/or lack of treatment option
information available, as demonstrated in the following
verbatim examples:
“I think that there are a lot of things lacking in terms
of what is available for speed [methamphetamine].I t
is all geared toward heroin and it just isn’tg o o d
enough. It is a very different detox and staff aren’t
trained to know what to expect”
“Generally, I think they [treatment services] are very
poor - I guess that’s understandable because they are
mainly targeted at heroin addicts. There’sac h a n g e
in drug taking habits and the options aren’t there for
other drugs”
Features of a responsive alcohol and drug treatment
service
The key features of what constitutes a responsive AOD
s e r v i c ew e r ed e s c r i b e db yt h es a m p l ea n dr e s p o n s e s
were coded into predominant themes (Table 4).
Of those participants who responded to the question
(n = 70), over 50% (n = 39) referred to the importance
of appropriate staff and their characteristics as a feature
of a good AOD service. Respondents highlighted the
need for staff that are friendly, supportive, non-
judgmental, compassionate, well trained and knowledgeable.
Table 2 Reasons for seeking methamphetamine
treatment
Reasons for seeking treatment n (%) (n = 43)
Sick of the lifestyle 28 (65%)
Pressure from family and friends 28 (65%)
Seeking abstinence 21 (49%)
Financial reasons 17 (40%)
Wanted ‘time out’ 13 (30%)
Legal reasons 13 (30%)
Health problems 10 (23%)
Wanted to reduce use 9 (21%)
Table 3 Barriers to methamphetamine treatment seeking
Barriers n (%) (n = 68)
Wanted to attempt to withdraw on own 35 (52%)
Didn’t know how to access treatment 28 (41%)
Wanted to keep using 26 (38%)
Unaware of the available treatment options 26 (38%)
Embarrassed or felt stigma attached to treatment 22 (32%)
Lack of support 21 (31%)
Cost/financial difficulties 14 (21%)
Work commitments 13 (19%)
Too hard to get into treatment 13 (19%)
Waiting lists too long/didn’t want to wait 12 (18%)
Little confidence in effectiveness 8 (12%)
Treatment goals not compatible with personal goals 8 (12%)
Table 4 Key features of a good AOD service
Key Features n % (n =
70)
Supportive staff 39 (56%)
Location (i.e., accessible by public transport, not too far to
travel)
15 (21%)
Suitable environment (i.e., calm, clean, quiet) 12 (17%)
Accessible opening hours (i.e., including outside of
business hours: evenings and weekends)
12 (17%)
Staff personally experienced with drug use 11 (16%)
Case management 9 (13%)
Immediate/quick appointment (i.e., no waiting lists) 9 (13%)
Accurate information made available 5 (7%)
Individually tailored treatment, with multiple treatment
options and client input
5 (7%)
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experience with methamphetamine users was important,
with 16% (n = 11) of respondents recognizing the benefits
of AOD workers who had personal experience with their
own drug use, or at least general life experience and
understanding of drug use and drug users.
While 21% (n = 15) of respondents highlighted loca-
tion as an important feature, these were divided into
those who believed an isolated location was beneficial
and those who felt a metropolitan location was
important.
Accessibility was cited as important factors by a num-
ber of respondents (17%, n = 12), with one participant
saying:
“It needs to be free, accessible, appointment quickly,
opening hours - shouldn’t have to wait too long to see
someone. When you’re going through these periods,
you don’t need another excuse not to go... At your
first point of contact even if you have a negative
experience at the counter, first person you talk to on
the phone, the first person you talk to is so impor-
tant. The smallest little f**k up on their part will
send you running straight back to the people who got
you there in the first place”
Some respondents also identified the need for case
management as part of drug treatment (13%; n = 9),
noting that their primary needs took precedence (i.e.,
access to safe and stable accommodation, regular
income and life skills), and they would not be prepared
to engage in specific treatment for their methampheta-
mine dependence until such factors were in control. For
example:
“Helping people to get some goals and having some-
thing to look forward to in life... Ask them what they
want to achieve and give them things to work for-
ward to. When they see some progress, then it’s like
savings - you get motivated to work harder to get
there”
Discussion and Conclusions
Research over a decade ago in the UK highlighted both
the low treatment attendance and perceived ineffective-
ness of methamphetamine treatment [13,14]. Today,
methamphetamine treatment access in Australia is rela-
tively low [4], and findings from this study indicate that
methamphetamine users perceive a number of barriers to
methamphetamine treatment. The current study provides
a snapshot of views about drug treatment and barriers to
treatment from the perspective of methamphetamine
users in the hope that targeted research can inform
treatment services about how to better orient themselves
towards this client group.
Treatment utilization amongst methamphetamine
users interviewed in this study was low despite respon-
dents claiming to be aware of treatment options. For
example, while 96% of respondents were aware that
counseling is available for methamphetamine depen-
dence, only 22% of the sample had accessed counseling,
and similarly only 15% of respondents had accessed
inpatient withdrawal despite awareness levels at 78%.
This indicates that awareness of treatment options is
not the main reason for low rates of treatment engage-
ment among methamphetamine users.
The three most common reasons identified for not
having sought treatment all indicated that methamphe-
tamine users did not think their use was serious enough
or problematic enough to warrant formal treatment,
despite these users having met DSM-IV criteria for
methamphetamine dependence at some stage during
their use. Furthermore, a common barrier to treatment
was that methamphetamine users simply wanted to keep
using. These findings suggest that methamphetamine
users might not be accessing treatment because: a) they
do not feel that they are dependent (i.e., DSM-IV cri-
teria doesn’t correlate with their own perceptions of
dependence), b) they don’t feel that regular use of
methamphetamine warrants formal treatment, c) they
discount their dependence, or d) they recognize their
dependence but are not ready to do anything about it
due to the benefits they receive from their drug use.
A focus on harm reduction (emphasizing things such as
improving physical health or psychosocial problems),
might be more useful for methamphetamine users who
are using heavily but not interested in formal treatment.
High levels of polydrug use were evident in the sam-
ple, and although methamphetamine was cited as the
most common drug of choice among participants, there
were also high rates of cannabis, heroin and alcohol
among the sample. All of these drugs have sedative and/
or depressant properties, which have the opposite effect
to stimulant drugs such as methamphetamine. This may
indicate that methamphetamine users either combine
such drugs to compliment or interact with the effects of
methamphetamine or use these drugs when they are not
using methamphetamine to help with symptoms of
withdrawal. Nevertheless this indicates that treatment
for methamphetamine should incorporate a focus on
other drug use.
For those methamphetamine users who sought treat-
ment, the main reasons included being sick of the life-
style, pressure from family and friends and seeking
abstinence. These methamphetamine users were most
likely to access counseling and inpatient withdrawal
treatment, followed by Narcotics Anonymous. Barriers
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generally include social stigma, perceptions about treat-
ment effectiveness, accessibility and long waiting periods
[8-12]. These were all barriers identified by participants
in this study, particularly issues around stigma and
treatment effectiveness which were cited as two of the
main barriers. Barriers identified by Wright, Klee and
Reid from over 10 years ago [13] that include metham-
phetamine users not identifying themselves as ‘hard’ or
dependent drug users and being unwilling to mix with
heroin users, were not as evident in this study. However,
some methamphetamine users did emphasize the ‘opi-
ate-centric’ nature of treatment and indicated a desire
for specialist treatment, or at the very least more specia-
lized training for staff who do not have sufficient knowl-
edge around the specific issues associated with
methamphetamine.
Barriers to methamphetamine withdrawal treatment
among service providers identified by Pennay and Lee
[15] were different from those of users in this study. For
example, mental health co-morbidity was not identified
as a problem, nor was the ‘binge’ nature of use. How-
ever, methamphetamine users did note that waiting per-
iods (resulting in drop out from treatment) and lack of
a specific pharmacotherapy were barriers to treatment.
Other barriers included the perceived negative attitudes
of staff, which appears to be confirmed by the Pennay
and Lee [15] study in which treatment staff voiced gen-
eral pessimism towards these clients.
Respondents preferred to undergo withdrawal from
methamphetamine on their own rather than seeking
professional help, perhaps due to the perceived negative
attitudes of staff and inappropriateness of services. Self-
detoxification was the most frequent method of withdra-
wal from methamphetamine cited by participants, who
frequently self-medicated to manage symptoms. This is
consistent with previous research identifying self-
detoxification as common among stimulant users [21].
Self-help materials to support and assist methampheta-
mine users through withdrawal may be useful in reducing
the risks associated with self-withdrawal (including the
concurrent use of other drugs), and could indicate the
point at which users should consider seeking professional
assistance if withdrawal becomes too difficult.
Other barriers noted included problems with availabil-
ity, such as waiting lists and limited treatment spaces.
One recent advancement towards improving accessibility
to methamphetamine treatment is the development of a
range of online services for drug use and mental health
problems [22]. Such services may offer a ‘soft entry’ to
formal treatment as well as important harm reduction
and self-help information for methamphetamine users.
Other barriers included the belief that methampheta-
mine treatment is inappropriate, ineffective and
incompatible with their personal goals. Methampheta-
mine users are asking for more efficient access to ser-
vices that are better oriented to their needs. Such needs
include counseling specific to methamphetamine use, a
pharmacotherapy to ease withdrawal symptoms and spe-
cialist centers that are more adequately equipped to
treat methamphetamine users. A treatment setting spe-
cific to methamphetamine users was identified in this
s t u d ya so n ew a yt oa c c o m m o d a t et h ev e r yd i f f e r e n t
nature of methamphetamine dependence and withdra-
wal compared to other drugs such as opiates.
In an attempt to overcome the well-established bar-
riers to methamphetamine treatment, four stimulant
specific clinics have been developed in Australia. In
2006, two specialist methamphetamine clinics, known as
‘The Stimulant Treatment Program’ (STP), were estab-
lished in Sydney and Newcastle. An evaluation of the
first six months of the STP clinics found that almost
half of the 87 clients had not previously sought formal
treatment for their methamphetamine use. Follow-up
interviews with clients showed that clients had reduced
their drug use considerably over the course of treat-
ment, as well as severity of dependence, distress, mental
health problems and crime, together with improvements
in social functioning. This preliminary evaluation
showed that the STP was feasible and was able to attract
methamphetamine users into treatment, particularly
those who weren’t attracted into mainstream treatments
[23].
In 2007, two specialist methamphetamine clinics
(’Access Point’) were established in the Melbourne sub-
urbs of Fitzroy and St Kilda. The Access Point model
was designed to address many perceived barriers to
methamphetamine treatment, including providing timely
service (i.e., no waiting periods), providing a waiting
area separated from other clients (addressing barriers
around methamphetamine users not wanting to mix
with heroin users) and providing specialised and tailored
methamphetamine treatment which included access to a
counselor, psychiatrist and medical practitioner. An eva-
luation of the clinics over the first twelve months of
operation showed that Access Point clients differed
demographically from clients receiving standard AOD
treatment, including being older, more likely to be
employed and more likely to be smoking methampheta-
mine than injecting. Access Point showed better out-
comes in term of treatment retention than standard
treatment. In addition, Access Point clients showed
good reductions in methamphetamine use and mental
health problems [24].
Although establishing an entirely separate clinic is
beyond the means of many drug treatment services, ser-
vices can undertake small changes that could have a
large impact on perceptions, such as allocating some
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methamphetamine users are seen or allocating specific
staff or rooms to methamphetamine treatment that con-
tain methamphetamine specific information and
resources. The former would also reduce waiting times,
another barrier to methamphetamine users entering
treatment, as there would be a time in which these cli-
ents could be booked in within a day or two.
This study has identified some barriers to metham-
phetamine treatment. However, we have identified a
number of ways in which treatment can be improved
for methamphetamine users, including access to treat-
ment through online programs, allocating a certain
amount of time or treatment space to methampheta-
mine users and improving capacity of clinicians to be
able to better respond to methamphetamine users.
Finally, more research needs to be undertaken to iden-
tify an appropriate pharmacotherapy to either assist in
the reduction of methamphetamine withdrawal symp-
toms or to act as a substitution treatment.
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